Slingshot members are tracking this event:

FDA Grants Pfizer's (PFE) Inotuzumab Ozogamicin Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 19, 2015
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Inotuzumab Ozogamicin, Acute Lymphoblastic Leukemia, Ino-vate All Trial, Phase 3, Breakthrough Therapy Designation